1-6 of 6
Ting Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Available to Purchase
Chun-Ping Chang, Teng-Kuang Yeh, Chiung-Tong Chen, Wan-Ping Wang, Yen-Ting Chen, Chia-Hua Tsai, Yan-Fu Chen, Yi-Yu Ke, Jing-Ya Wang, Ching-Ping Chen, Tsung-Chih Hsieh, Mine-Hsine Wu, Chen-Lung Huang, Ya-Ping Chen, Hong Zhuang, Ya-Hui Chi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (6): 766–779.
https://doi.org/10.1158/1535-7163.MCT-23-0602
Published: 04 June 2024
View articletitled, Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus
Open the PDF for Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus in another window
Includes: Supplementary data
Journal Articles

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Open Access
Andrea T. Hooper, Kimberly Marquette, Chao-Pei Betty Chang, Jonathon Golas, Sadhana Jain, My-Hanh Lam, Magali Guffroy, Mauricio Leal, Hadi Falahatpisheh, Divya Mathur, Ting Chen, Kerry Kelleher, Kiran Khandke, Elwira Muszynska, Frank Loganzo, Edward Rosfjord, Judy Lucas, Zhengyan Kan, Chakrapani Subramanyam, Christopher O'Donnell, Dario Neri, Hans-Peter Gerber, Chad May, Puja Sapra
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (9): 1462–1472.
https://doi.org/10.1158/1535-7163.MCT-22-0099
Published: 06 September 2022
View articletitled, Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
Open the PDF for Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling

Free
Xiangyan Li, Yi-Ting Chen, Peizhen Hu, Wen-Chin Huang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (4): 855–866.
https://doi.org/10.1158/1535-7163.MCT-13-0797
Published: 06 April 2014
View articletitled, Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling
Open the PDF for Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract A5: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade.

Free
William Winston, Luhua Shen, Guangmu Li, Sandra Abbott, Ting Chen, Jinwei Jiang, Solly Weiler, Samantha Perino, Ronan O'Hagan, Murray O. Robinson, M. Isabel Chiu, Jeno Gyuris, Jie Lin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A5.
https://doi.org/10.1158/1535-7163.TARG-11-A5
Published: 12 November 2011
View articletitled, Abstract A5: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade.
Journal Articles

Src tyrosine kinase as a therapeutic target in ovarian cancer and multidrug-resistant ovarian cancer

Free
Ting Chen, Zuxuan Wang, Tim Green, Christopher Taylor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A235.
Published: 01 November 2007
View articletitled, Src tyrosine kinase as a therapeutic target in ovarian cancer and multidrug-resistant ovarian cancer
Journal Articles

Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3

Free
Ting Chen, Yolande Pengetnze, Christopher C. Taylor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (2): 217–224.
https://doi.org/10.1158/1535-7163.217.4.2
Published: 15 February 2005
View articletitled, Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3
Open the PDF for Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3 in another window